290 research outputs found
Gene expression profiles of 4âhydroxyâNâdesmethylâtamoxifen (endoxifen)â and 4âhydroxyâtamoxifen (4OHTAM)âtreated human breast cancer cells determined by CDNA microarray analysis
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109798/1/cptclpt2004192.pd
Menopausal status and estrogen receptor genotypes influenced the severity of hot flashes after tamoxifen treatment
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109844/1/cptclpt200521.pd
Estrogen Receptor Genotypes, Menopausal Status, and the Effects of Tamoxifen on Lipid Levels: Revised and Updated Results
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109960/1/cptclpt2010143.pd
Piâ29
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110026/1/cptclpt200664.pd
Piiâ18
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110052/1/cptclpt2006156.pd
Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109858/1/cptclpt2011174.pd
Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109885/1/cpt6100343.pd
How informative is a negative finding in a small pharmacogenetic study?
Many pharmacogenetic studies fail to yield any statistically significant associations. Such negative findings may be due to the absence of, or inadequate statistical power to test for, an effect at the genetic variants tested. In many instances, sample sizes are small, making it unclear how to interpret the absence of statistically significant findings. We demonstrate that the amount of information that can be drawn from a negative study is improved by incorporating statistical power and the added context of well-validated pharmacogenetic effects into the interpretation process. This approach permits clearer inferences to be made about the possible range of genetic effects that may be present in, or are likely absent from, small drug studies
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects
Background:
Change in breast density may predict outcome of women receiving adjuvant hormone therapy for breast cancer. We performed a prospective clinical trial to evaluate the impact of inherited variants in genes involved in oestrogen metabolism and signalling on change in mammographic percent density (MPD) with aromatase inhibitor (AI) therapy.
Methods:
Postmenopausal women with breast cancer who were initiating adjuvant AI therapy were enrolled onto a multicentre, randomised clinical trial of exemestane vs letrozole, designed to identify associations between AI-induced change in MPD and single-nucleotide polymorphisms in candidate genes. Subjects underwent unilateral craniocaudal mammography before and following 24 months of treatment.
Results:
Of the 503 enrolled subjects, 259 had both paired mammograms at baseline and following 24 months of treatment and evaluable DNA. We observed a statistically significant decrease in mean MPD from 17.1 to 15.1% (P<0.001), more pronounced in women with baseline MPD â©Ÿ20%. No AI-specific difference in change in MPD was identified. No significant associations between change in MPD and inherited genetic variants were observed.
Conclusion:
Subjects with higher baseline MPD had a greater average decrease in MPD with AI therapy. There does not appear to be a substantial effect of inherited variants in biologically selected candidate genes
- âŠ